VHL and neoplasm: Identification of the von Hippel-Lindau (VHL) tumor suppressor gene in 1993 (6) and subsequent discovery of a high rate of VHL gene mutations in patients with sporadic RCC (7) formed the theoretical basis for molecular targeting drugs for advanced RCC, such as tyrosine kinase and mammalian target of rapamycin inhibitors.